| Chemical Information | |
| Antiviral agent ID | DrugRepV_7220 | |
| Antiviral agent name | SA-17 | |
| Structural Information | |
| 2-D Structure is not available | 3-D Structure is not available |
| Clinical Information | |
| Biological Information | |
|
Secondary Indication | Yellow fever virus (YFV) NA 17D |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | Vero-B
| |
|
Secondary Indication (Viral titer) | 1000000 PFU
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Drug concentration) | 2.9 ± 1.8 μM
| |
|
Secondary Indication (Cell based assay) | qRT-PCR
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
|
Reference | Kaptein SJ, De Burghgraeve T, Froeyen M, Pastorino B, Alen MM, Mondotte JA, Herdewijn P, Jacobs M, de Lamballerie X, Schols D, Gamarnik AV, Sztaricskai F, Neyts J..A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro..Antimicrob Agents Chemother. 2010 Dec;54(12):5269-80. doi: 10.1128/AAC.00686-10. Epub 2010 Sep 13. P PMID:20837762
|  |
|
Comment | Time-of-drug-addition studies revealed that SA-17 acts at the very early stages of the viral replication cycle (i.e., virus attachment and/or virus entry). This observation was corroborated by the observation that SA-17 does not inhibit the replication of DENV subgenomic replicons.
| |